Hypertension Guidelines Explained. What Changes for Your Treatment

The 2025 AHA/ACC hypertension guideline — still the current reference, with three corrections published between December 2025 and June 2026 — moves home and ambulatory blood pressure monitoring from a helpful adjunct to a central pillar of diagnosis and management, and reaffirms a treatment target of below 130/80 mm Hg for most adults. In May 2026, the FDA approved Baxfendy (baxdrostat), the first radically new antihypertensive drug class in decades: an aldosterone synthase inhibitor. For clinicians practicing remotely, the picture in 2026 is clear: modern hypertension care is built around out-of-office data, risk-stratified pharmacotherapy, and structured follow-up — precisely the workflow that telemedicine is designed to deliver.

What Actually Changed in the 2025 Guideline (and the 2026 Updates)

The 2025 AHA/ACC guideline, published in August 2025, is the first comprehensive update since 2017. Three subsequent corrections — December 2025, May 2026, and June 2026 — have refined specific sections without modifying the core diagnostic thresholds or treatment targets.

The headline number is stable: a general BP goal of <130/80 mm Hg, with explicit encouragement to reach <120/80 mm Hg when it can be achieved safely. Exceptions apply for patients in institutional care, those with limited life expectancy, and pregnancy, where individualized targets remain appropriate.

The most consequential methodological change is the adoption of the PREVENT risk calculator, which replaces the Pooled Cohort Equations. PREVENT estimates 10-year and 30-year total cardiovascular disease risk in adults aged 30–79 and incorporates kidney function, statin use, and social drivers of health — giving remote clinicians a more complete risk picture from data that is often already available in the chart.

Terminology also evolved: "hypertensive urgency" has been replaced with "severe hypertension", aligning nomenclature with current evidence on management and prognosis.

Two updates from 2025–2026 deserve specific attention:

Primary aldosteronism screening — Endocrine Society 2025: Updated guidelines now recommend screening all hypertensive patients, not only those with stage 2 or resistant disease. This expansion detected 92% more cases in study cohorts (prevalence 16.1% vs. 8.8% with prior criteria). Confirmatory testing with saline infusion is no longer required; diagnosis rests on the biochemical triad of suppressed renin, elevated aldosterone, and elevated aldosterone-to-renin ratio. Most antihypertensives can continue during screening, making integration into remote workflows straightforward.

Renal denervation — SPYRAL 3-year data (October 2025): The 36-month results of SPYRAL HTN-ON MED confirmed durable benefit: a treatment difference of −7.4 mm Hg in office systolic BP vs. sham (p=0.0002) and −4.7 mm Hg in 24-hour ambulatory BP (p=0.0028). The real-world GSR-DEFINE registry showed a −20.5 mm Hg office BP reduction at 3 years and a 43% reduction in acute hypertensive events. The FDA had already approved renal denervation systems in November 2023; Medicare issued coverage in October 2025. The guideline retains this option as Class IIb for resistant hypertension despite optimal therapy or drug intolerance.

Remote Blood Pressure Monitoring Is Now Standard of Care

The guideline states plainly that home blood pressure monitoring (HBPM) and ambulatory blood pressure monitoring (ABPM) are central to both diagnosis and management. For a telemedicine practice, this is not a constraint — it is validation of the model.

Why out-of-office readings matter

Office readings alone systematically misclassify patients. Out-of-office monitoring identifies white-coat hypertension (elevated in clinic, normal at home), which prevents overtreatment, and masked hypertension (normal in clinic, elevated at home), which prevents dangerous undertreatment. ABPM adds the ability to detect nocturnal hypertension and non-dipping patterns that carry independent cardiovascular risk.

Getting the measurement right remotely

The reliability of remote management depends entirely on measurement quality. When onboarding a patient to HBPM, confirm the following:

• A validated, upper-arm oscillometric device. The guideline explicitly does not recommend cuffless devices for diagnosis or treatment decisions.
• Correct cuff size, matched to arm circumference — an undersized cuff overestimates BP.
• Standardized technique: seated, back supported, feet flat, arm at heart level, after five minutes of rest, with no caffeine or exercise in the preceding 30 minutes.
• A structured protocol: duplicate morning and evening readings over seven days, discarding day one, then averaging the remainder.

A short video onboarding during a [telemedicine consultation](https://aliviaq.com/services) is often more effective than written instructions and lets you observe the patient's technique directly.

When to prefer ABPM

While HBPM covers most patients, consider 24-hour ABPM when home and office readings disagree, when you suspect nocturnal hypertension or a non-dipping pattern, when evaluating apparent resistant hypertension before adding a fourth agent, or when assessing symptomatic hypotension on treatment. ABPM remains the reference standard, and a single 24-hour study can resolve diagnostic uncertainty that weeks of intermittent office visits would not.

Cognitive Protection: The New Reason to Reach <130 mm Hg

The 2025 guideline elevates controlling systolic BP below 130 mm Hg to a Level 1A recommendation for the prevention of mild cognitive impairment and dementia — a clinically significant addition that changes how you frame BP targets with older patients.

The evidence base is robust:

• The SPRINT-MIND trial demonstrated a 19% reduction in mild cognitive impairment and a 15% reduction in the combined outcome of MCI/dementia with a systolic target of <120 mm Hg vs. <140 mm Hg.
• A recent meta-analysis estimates a 13% reduction in dementia risk with sustained antihypertensive therapy.
• Midlife hypertension is associated with a 60% higher dementia risk and a 25% higher Alzheimer's risk later in life (Alzheimer's & Dementia, 2025).

For remote clinicians, this is a practical communication tool: for patients who have reached <130/80 mm Hg but not yet <120/80 mm Hg, cognitive protection provides an additional, evidence-based argument to review the regimen — if their overall condition permits.

Risk-Stratified Pharmacotherapy in the Virtual Clinic

The 2025 guideline ties the decision to treat more tightly to global risk rather than BP alone — a framework that maps cleanly onto structured remote decision-making.

For higher-risk patients — those with established cardiovascular disease, diabetes, chronic kidney disease, or an estimated 10-year CVD risk of ≥7.5% by PREVENT — pharmacotherapy is recommended at BP ≥130/80 mm Hg. For lower-risk patients (<7.5%), medication is reserved for BP that remains ≥130/80 mm Hg after 3–6 months of structured lifestyle intervention.

Initiation strategy follows stage:

• Stage 1 (130–139/80–89 mm Hg): a single first-line agent is reasonable.
• Stage 2 (≥140/90 mm Hg): begin with two first-line agents, ideally as a single-pill combination (SPC) to improve both control and adherence.

The first-line classes remain thiazide-type diuretics, long-acting dihydropyridine calcium channel blockers, and ACE inhibitors or ARBs (never an ACEi and ARB together).

Pharmacological updates in 2025–2026

GLP-1 receptor agonists: reduce systolic BP by 2–5 mm Hg in monotherapy, with greater reductions (5–7 mm Hg) observed with dual or triple agonists. Approximately 68–89% of this reduction is mediated by weight loss; the remainder comes from renal natriuresis and endothelial improvement. The magnitude is smaller than traditional antihypertensives (7–11 mm Hg) but clinically meaningful in patients with hypertension and overweight or obesity. Note: a modest heart rate increase of 2–5 bpm has been observed.

Baxfendy (baxdrostat) — FDA-approved May 18, 2026: The first aldosterone synthase inhibitor (ASI) approved for clinical use. It works by reducing aldosterone synthesis, thereby lowering sodium and water retention. Indicated as combination therapy for uncontrolled hypertension in adults, at doses of 1–2 mg once daily. The pivotal trial published in the New England Journal of Medicine demonstrated superiority over placebo in reducing seated BP. Main adverse effects: hyperkalemia (6.6% at 1 mg; 10.2% at 2 mg), hypotension, hyponatremia, dizziness. Particularly relevant in resistant hypertension with confirmed or suspected hyperaldosteronism.

Because SPCs and simple titration schedules travel well over telemedicine, remote practice is arguably better positioned than episodic in-person care to execute the guideline's emphasis on early combination therapy and prompt follow-up. When a case involves resistant hypertension, secondary causes, or end-organ complications, [find a specialist](https://aliviaq.com/doctors) for co-management rather than extending empiric titration.

Building a Telemedicine Hypertension Protocol

The guideline's strongest implementation signal is its endorsement of team-based care — pharmacists, nurses, and community health workers operating under protocol, supported by telehealth and mobile tools. A practical remote protocol has four components.

1. Intake and risk stratification. Confirm the diagnosis with HBPM or ABPM, calculate PREVENT risk, and screen for primary aldosteronism in all hypertensive patients (Endocrine Society 2025) via a plasma aldosterone-to-renin ratio.

2. Lifestyle as foundational therapy. These interventions are first-line for every patient, not a footnote:

• Sodium <2,300 mg/day, with <1,500 mg/day desirable where appropriate.
• Potassium 3,500–5,000 mg/day, preferably from diet — unless the patient has CKD or is on potassium-sparing agents.
• DASH-style eating pattern.
• ≥5% weight loss as an initial goal in patients with overweight or obesity.
• Physical activity, alcohol moderation, and structured stress management, the last of which the 2025 guideline explicitly elevates.

3. Titration cadence. Reassess BP with home data at roughly 2–4 week intervals after any change until goal is reached, then space follow-up as control stabilizes. Structured remote check-ins reduce clinical inertia, a leading driver of uncontrolled hypertension.

4. Escalation criteria. Define in advance when a virtual encounter must convert to in-person or emergency care — severe hypertension with symptoms, signs of end-organ damage, or a BP crisis. When ongoing management is appropriate, patients can [book an appointment](https://aliviaq.com/book) for follow-up without the barriers of travel and clinic wait times.

The Bottom Line for Clinicians

The 2025 AHA/ACC guideline — updated through 2026 — did not merely tweak numbers. It reoriented hypertension care around out-of-office data, global risk, cognitive protection, and continuous follow-up. The arrival of Baxfendy and the expansion of primary aldosteronism screening to all hypertensive patients open new diagnostic and therapeutic pathways for the most difficult-to-control cases. Each of these pillars is a natural strength of telemedicine. Clinicians who build validated home monitoring, PREVENT-based risk stratification, single-pill combination therapy, and protocolized team-based follow-up into their remote workflow are not adapting to the guideline — they are practicing exactly the way it now recommends.

Frequently Asked Questions

Does the 2025 guideline change the definition of hypertension? No. The diagnostic thresholds are unchanged — elevated BP at 120–129/<80 mm Hg, stage 1 at 130–139/80–89 mm Hg, and stage 2 at ≥140/90 mm Hg. What changed is the treatment target (reaffirmed at <130/80 with encouragement toward <120/80), the risk tool (PREVENT), the terminology ("severe hypertension" replacing "hypertensive urgency"), and the emphasis on out-of-office monitoring.

Can I diagnose and manage hypertension entirely through telemedicine? For most patients, yes — provided diagnosis rests on validated home or ambulatory readings rather than cuffless devices, and you have clear criteria for when in-person evaluation is required. Team-based remote care with structured follow-up aligns directly with the guideline's recommendations.

When should I screen for primary aldosteronism? The 2025 Endocrine Society guidelines now recommend screening all hypertensive patients, regardless of stage or potassium level. A plasma aldosterone-to-renin ratio is the first-line test, and most antihypertensives can continue during screening. This expanded approach detects 92% more cases than prior criteria, identifying a treatable secondary cause that was previously missed.

What is Baxfendy and who is it for? Baxfendy (baxdrostat) is the first aldosterone synthase inhibitor approved by the FDA (May 2026). It is indicated as add-on therapy for adults with uncontrolled hypertension, particularly those with suspected or confirmed aldosterone excess. Potassium and blood pressure require monitoring at initiation.